ESGO-ESMO-ESP 卵巢癌共识会议推荐:病理与分子生物学及早期、晚期和复发疾病
欧洲妇科肿瘤学会、欧洲肿瘤内科学会与欧洲病理学会于2022年6月15-16日在西班牙瓦伦西亚召开卵巢癌共识会议,44位专家参与,围绕病理与分子生物学、早期疾病与妊娠期盆腔包块、晚期疾病(含年老/虚弱患者)及复发疾病四大主题的18个问题制定推荐,经全体讨论修正后投票形成共识推荐。
要点
- 共识会议涵盖卵巢癌病理与分子生物学、早期、晚期及复发疾病四大主题。
- 44位专家参与,18个问题经工作组制定推荐后全体投票形成共识。
- 本文聚焦达成共识的推荐声明、投票结果及支持证据摘要。
核心结论
- 会议针对卵巢癌病理与分子生物学、早期和晚期及复发疾病制定并投票形成共识推荐,旨在改进和统一患者管理。
研究设计与样本
- 欧洲妇科肿瘤学会、欧洲肿瘤内科学会与欧洲病理学会于2022年6月15-16日在西班牙瓦伦西亚召开共识会议。
- 共识小组包括44位卵巢癌管理与病理学专家、1位ESMO科学顾问和1位方法学家。
- 会议确定18个问题,分属病理与分子生物学、早期疾病与妊娠期盆腔包块、晚期疾病(含年老/虚弱患者)和复发疾病四个主题。
- 小组按专长分为四个工作组,预先复习相关科学文献,制定推荐后提交全体小组讨论修正并投票。
主要发现
- 本文聚焦达成共识的推荐声明、其投票结果及支持每条推荐的证据摘要。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.
引用
- Ledermann JA, Matias-Guiu X, Amant F, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024. PMID: 38307807. doi:10.1016/j.annonc.2023.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。